Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: An Indian study☆

Siddiqui, M.K.J.; Kumari, Jyoti; Singh, Surendra; Mehrotra, Prateek K.; Singh, Kanika; Sarangi, Rathindra

doi:10.1016/j.envint.2006.02.002

Cited by 79 publications

(67 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, except for Fe, all element concentrations are higher in benign tissues than in malignant ones. It is important to note that these data are in agreement with other studies [4,9,35,36] and may be associated with different structural and metabolic aspects, [15,37,38] as well as with tumor development. [39] The results of the Wilcoxon test (paired samples) and the Mann-Whitney test (independent samples) showed that, with the exception of iron and copper, all trace elements studied have a concentration distribution with significant differences when comparing normal and neoplastic tissues (benign or malignant).…”

Section: Trace Element Concentrationssupporting

confidence: 90%

Role of Ca, Fe, Cu and Zn in breast cancer: study by X‐ray fluorescence techniques and immunohistochemical analysis

Silva¹,

Silva²,

Conceição³

et al. 2013

X-Ray Spectrometry

View full text Add to dashboard Cite

a In recent years, several studies have shown that concentrations of trace elements are altered in neoplastic breast tissues. However, the microenvironment and metabolic changes caused by tumors are complex and still not completely understood. Under this aspect, the combination of different techniques to investigate the role of trace elements in promoting and/or maintaining a tumor is interesting once the combination of information obtained by analytical techniques and immunohistochemical assays, associated with clinicopathological data, may allow a better metabolic understanding of trace elements in breast cancer.In this work, the role of the trace elements Ca, Fe, Cu and Zn in neoplastic breast tissues was investigated by X-ray fluorescence (XRF) techniques and immunohistochemical assays. We determined concentrations of Ca, Fe, Cu and Zn in normal and neoplastic breast tissues using energy dispersive XRF, and these values were used to set the positive or negative expression of elements in normal and neoplastic tissues. These expressions were correlated with the spatial distributions of trace elements (evaluated by micro-XRF) and with immunoexpression of matrix metalloproteinases (MMPs), tissue inhibitors of MMPs and vascular endothelial growth factor.The results revealed that the expression of the trace elements Fe, Cu and vascular endothelial growth factor are related, indicating that higher levels of these elements can be associated with the angiogenic process in breast cancer. Also, associations between Ca, Zn and MMPs expression have been observed, possibly because of the fact that both metals are present in these proteins.

show abstract

Section: Trace Element Concentrationssupporting

confidence: 90%

Role of Ca, Fe, Cu and Zn in breast cancer: study by X‐ray fluorescence techniques and immunohistochemical analysis

Silva¹,

Silva²,

Conceição³

et al. 2013

X-Ray Spectrometry

View full text Add to dashboard Cite

show abstract

“…Systemic iron homeostasis is strictly fine-tuned through various mechanisms, of which the hepcidin-FPN axis fundamentally governs the global iron absorption, distribution, utilization, and egress [48]. However, disordered iron metabolism would likely give rise to a large array of dysfunctions, morbidities and even diseases, such as cancers [5,[49][50][51][52][53]. In fact, a myriad of epidemiological studies have documented a considerable contribution of elevated body iron to cancer risk of occurrence and prognosis [52][53][54][55][56][57].…”

Section: Discussionmentioning

confidence: 99%

“…However, disordered iron metabolism would likely give rise to a large array of dysfunctions, morbidities and even diseases, such as cancers [5,[49][50][51][52][53]. In fact, a myriad of epidemiological studies have documented a considerable contribution of elevated body iron to cancer risk of occurrence and prognosis [52][53][54][55][56][57]. In stark contrast to normal cells, iron demand is remarkably enforced in cancer cells to meet the enhanced cellular activities including DNA synthesis and energy generation [58,59].…”

Section: Discussionmentioning

confidence: 99%

Estrogen contributes to regulating iron metabolism through governing ferroportin signaling via an estrogen response element

Qian

Yin

Chen

et al. 2015

Cellular Signalling

View full text Add to dashboard Cite

Ferroportin (FPN) is the only known iron exporter in mammalian cells, and is universally expressed in most types of cells. FPN signaling plays a crucial role in maintaining iron homeostasis through governing the level of intracellular iron. Serum iron storage is conversely related with the estrogen level in the female bodies, and women in post-menopause are possibly subjected to iron retention. However, the potential effects of estrogen on iron metabolism are not clearly understood. Here, FPN mRNA transcription in all selected estrogen receptor positive (ER+) cells was significantly reduced upon 17β-estradiol (E2) treatment; and this inhibitory effect could be attenuated by ER antagonist tamoxifen. Likewise, in murine bone marrow-derived macrophages (BMDMs), FPN reduction with elevated intracellular iron (reflected by increased ferritin) was observed in response to E2; however, ferritin level barely responded to E2 in FPN-null BMDMs. The observation of inhibition of FPN mRNA expression was not replicated in ER − cells upon E2. A functional estrogen response element (ERE) was identified within the promoter of FPN, and this ERE was responsible for the suppressive effect of E2 on FPN expression. Moreover, ovariectomized (OVX) and sham-operated (SHAM) mice were used to further confirm the in vitro finding. The expression of hepatic FPN was induced in OVX mice, compared to that in the SHAM mice. Taken together, our results demonstrated that estrogen is involved in regulating FPN expression through a functional ERE on its promoter, providing additional insights into a vital role of estrogen in iron metabolism.

show abstract

“…Cancers are often associated with disordered systemic iron homeostasis [53,54], which in turn promotes tumor development through various signaling pathways, such as iron-induced cell growth and oxidative stress [34,55,56]. Clinical studies have noted that there is a positive correlation between body iron burden and the risk of developing tumors [34,57]. Although a number of studies have documented that diminishing iron supply to tumor cells could impede tumor growth in experimental models [58,59] and even patients with various cancers [60,61], the molecular bases of the altered iron homeostasis keep largely unexplored in cancers thus far.…”

Section: Discussionmentioning

confidence: 99%

Disordered hepcidin–ferroportin signaling promotes breast cancer growth

Zhang

Chen

Guo

et al. 2014

Cellular Signalling

111

136

View full text Add to dashboard Cite

Iron homeostasis is strictly governed in mammals; however, disordered iron metabolism (such as excess iron burden) is recognized as a risk factor for various types of diseases including cancers. Burgeoning evidence indicates that the central signaling of iron homeostasis, the hepcidin-ferroportin axis, is misregulated in cancers. Nonetheless, the mechanisms of misregulated expression of iron-related genes along this signaling in cancers remain largely unknown. In the current study, we found increased levels of serum hepcidin in breast cancer patients. Reduction of hepatic hepcidin through administration of heparin restrained tumorigenic properties of breast tumor cells. Mechanistic investigation revealed that increased iron, bone morphogenetic protein-6 (BMP6) and interleukin-6 (IL-6) jointly promoted the synthesis of hepatic hepcidin. Tumor hepcidin expression was marginally increased in breast tumors relative to adjacent tissues. In contrast, tumor ferroportin concentration was greatly reduced in breast tumors, especially in malignant tumors, compared to adjacent tissues. Elevation of ferroportin concentration inhibited cell proliferation in vitro and in vivo by knocking down tumor hepcidin expression. Additionally, increased IL-6 was demonstrated to jointly enhance the tumorigenic effects of iron through enforcing cell growth. Our combined data overall deciphered the machinery that altered the hepcidin-ferroportin signaling in breast cancers. Thus, targeting the hepcidin-ferroportin signaling would represent a promising therapeutics to restrain breast cancer growth.

show abstract

Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: An Indian study☆

Cited by 79 publications

References 27 publications

Role of Ca, Fe, Cu and Zn in breast cancer: study by X‐ray fluorescence techniques and immunohistochemical analysis

Role of Ca, Fe, Cu and Zn in breast cancer: study by X‐ray fluorescence techniques and immunohistochemical analysis

Estrogen contributes to regulating iron metabolism through governing ferroportin signaling via an estrogen response element

Disordered hepcidin–ferroportin signaling promotes breast cancer growth

Contact Info

Product

Resources

About